

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-12 (Cancelled).

13. (New): A method for the treatment of hyperglycaemia wherein plasma glucose levels are in the range from >126mg/dl to 140mg/dl, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof.

14. (New): A method according to claim 13, wherein the hyperglycaemia is fasting hyperglycaemia.

15. (New): A method according to claim 13, comprising administering 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, per day.

16. (New): A method according to claim 13, wherein the 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is in the form of a composition adapted for oral administration.

17. (New): A method according to claim 16, wherein the composition is in unit dosage form.

18. (New): A method according to claim 13, which comprises administering 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, per day.

19. (New): A method according to claim 13, which comprises administering 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, per day.

20. (New) A method according to claim 13, which comprises administering 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, per day.

21. (New): A method according to claim 13, which comprises administering 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

22. (New): A method according to claim 13, wherein said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or tautomer thereof is in the form of a pharmaceutically acceptable salt.

23. (New) A method according to claim 22, wherein said pharmaceutically acceptable salt is a maleate salt.

24. (New): A method according to claim 14, wherein the fasting plasma glucose level of said fasting hyperglycaemia is in the range of from >126mg/dl to 140mg/dl.

25. (New) A method according to claim 24, further comprising treating hyperglycemia, wherein the plasma glucose level following an oral glucose tolerance test is <140 mg/dl.

26. (New): A method according to claim 24, further comprising treating hyperglycemia, wherein the plasma glucose level following an oral glucose tolerance test is from 140 to <200 mg/dl.